Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Phase 1, Single-Center, Single-Ascending Dose Study of JZP-386 Compared to Xyrem® vs. Placebo to Evaluate the Safety and Pharmacokinetics

NCT02215499 is registered in ClinicalTrials.gov with Concert Pharmaceuticals as lead sponsor.

NCT NCT02215499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02215499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Phase 1, Single-Center, Single-Ascending Dose Study of JZP-386 Compared to Xyrem® vs. Placebo to Evaluate the Safety and Pharmacokinetics
Lead sponsor
Concert Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2014
Completion date
November 30, 2014
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

narcolepsy, excessive daytime sleepiness